

Lancet Respiratory Medicine Commentary

Title

The United Nations High-Level Meeting on Tuberculosis 2023: renewing the momentum and commitment to end TB

Authors

Kerry A. Millington,¹ Richard G. White,² Marc Lipman,³ C Finn McQuaid,² Janika Hauser,⁴ Fatima Karmadwala,⁵ Vincent Wooding,⁶ Jessica Potter,³ Ibrahim Abubakar,³ Tom Wingfield^{1,7*}

1 Liverpool School of Tropical Medicine, UK

2 TB Centre and Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

3 University College London, UK

4 Campaigns in Global Health, UK

5 World Health Organization Civil Society Task Force on Tuberculosis

6 RESULTS, UK

7 World Health Organization Collaborating Centre on Tuberculosis and Social Medicine, Department of Global Public Health, Karolinska Institutet, Sweden

Correspondence

*Dr Tom Wingfield Tom.Wingfield@lstmed.ac.uk

Liverpool School of Tropical Medicine, Wolfson Building, Pembroke Place, L3 5QA

The first ever 2018 United Nations High Level Meeting (HLM) on tuberculosis (TB) was widely welcomed as a necessary reaffirmation of the commitments in the WHO End TB Strategy and the UN Sustainable Development Goals to end TB by 2030, and a recognition that global efforts to end TB had saved an estimated 75 million lives this century.^{1,2} However, the limited progress made in TB prevention and care in the years following the 2018 HLM were decimated by the COVID-19 pandemic, which adversely affected access to TB services and financing, and intensified key social determinants of TB, including poverty and undernutrition.^{3,4} In 2020, while healthcare and scientific resources were ploughed into addressing COVID-19, it was estimated that 30,000 people developed TB disease and 4000 people died from TB every day.² Indeed, TB has now reclaimed from COVID-19 the unfortunate position of being the world's leading infectious killer and drug-resistant TB represents a leading cause of death due to antimicrobial resistance (AMR).⁵

In September 2023, following three High-Level Meetings (HLM) at the 78th Session of the United Nations General Assembly in New York, political declarations on pandemic prevention, preparedness and response; universal health coverage (UHC); and TB were adopted. Collectively, these consecutive HLMs were an historic opportunity to coordinate the TB community's collective voice and align across three complementary political agendas with a renewed sense of hope after the ravages of the COVID-19 pandemic. As members of [UK Academics and Professionals Against TB](#), an organization committed to ending TB through campaigns, advocacy, and education, we are proud to be part of this wider TB community and to have contributed to both UN HLMs on TB. Specifically, this year, we engaged tirelessly with TB civil society, healthcare professionals, public servants, and politicians in the UK and beyond to advocate for key improvements to the zero draft of the 2023 political declaration of the HLM on TB.

Following the HLM on TB, we were encouraged that the final adopted political declaration contained specific, measurable, and time-bound targets related to TB care, prevention, and funding; and, for the first time ever in a health related UNHLM declaration, recognised 'the right to enjoy and share the benefits of scientific progress'.⁶ Yet, despite these hard-won successes, the HLM on TB has been criticised as a missed opportunity and there remain concerns about how member states will be held accountable for the pledges they made.⁷⁻⁹ Negotiations were overshadowed by a range of political agendas, high-level political ambition was largely absent including from high burden countries, only a single Head of State spoke during the plenary on TB, and many pledges within the adopted declaration lacked clarity. For example, although undernutrition, stigma and discrimination were recognised as key determinants of both TB disease and adverse TB treatment outcomes, targets against which to measure progress to address these determinants were absent. Moreover, the final pledges had notable omissions including a lack of consideration of involvement of TB-affected communities and many numeric or time-bound targets being watered down with "up to" or "preferably within" language, representing ceilings rather than minimal expectations.

However, despite this lacklustre backdrop, it was impressive to see the commitments the TB community was able to secure. Key commitments included: measurable TB diagnosis and treatment targets; strengthened language on the importance of developing and rolling out a new, effective TB vaccine; recognition of the gendered impact of TB and the need to adopt equitable, inclusive, and gender-responsive approaches; and an explicit commitment to alleviate the financial burden of TB, by strengthening social protection and socioeconomic support, including beyond the health sector.

There were additional reasons the HLM on TB should generate positivity and optimism amongst the TB community. Global summits, such as HLMs, garner momentum and create space for the development and announcement of concrete commitments beyond the declarations themselves. The HLM on TB was no exception with several major initiatives launched on its fringes. These included the inauguration of the TB Vaccine Accelerator Council, supported by the WHO secretariat, which aims to

catalyse high-level commitment, engagement, and alignment among funders, global agencies, governments, and communities, and overcome barriers to equitable TB vaccine development, licensing, manufacture, and distribution at scale.¹⁰ There was also the launch of the Coalition of Leaders to End TB, involving Ministers of Health from Brazil, Indonesia, Kazakhstan, Kenya, Philippines, South Africa, and Tanzania. The Coalition aims to facilitate coordinated high-level national engagement and accountability for HLM pledges, and it is anticipated that other countries will join its membership shortly.¹¹ Finally, vital financial commitments to support TB research programmes were made including £5 million from the UK government to the TB Alliance and \$25 million USD from the Canadian government to TB Reach.

Whilst the final pledges are political and not legally binding, the HLM on TB is a process that goes well beyond a single declaration. By bringing political actors together with people and communities affected by TB, civil society, researchers, healthcare workers, the private sector and development partners, we can work in concert to prioritise and adequately finance TB research, development, policy, and practice, and more effectively hold governments and the whole TB community accountable to the promises made to end the TB epidemic by 2030.^{12,13} Even more can be achieved when we align across multiple HLMs through smarter investment, equitable access, and stronger more resilient health systems. Such alignment will be critical in the work ahead of the upcoming HLM on AMR in 2024.

Thirty years on from WHO's 1993 declaration, TB remains a global public health emergency. Despite the adopted political declaration of the 2023 TB HLM being underwhelming, the renewed momentum within the TB community must turn the positive pledges of that Declaration into action. This work must begin now – we cannot wait for the next UNHLM on TB, scheduled for 2028. We, UKAPT, will continue to collaborate with national and international stakeholders to lobby, advocate, and support delivery of the HLM commitments to ensure the immense efforts made to adopt the Declaration were worth it.

References (all hyperlinks accessed 13th October 2023)

1. [World Health Organization Global Tuberculosis Report 2022](#). World Health Organization, Geneva. Accessed 13th October 2023.
2. [World Health Organization Global Tuberculosis Report 2021](#). World Health Organization, Geneva. Accessed 13th October 2023.
3. [Status Update: Reaching The Targets In The Political Declaration Of The United Nations General Assembly High-Level Meeting On The Fight Against Tuberculosis September 2023](#). World Health Organization, 2023. Accessed 13th October 2023.
4. [Comprehensive review of progress towards the achievement of global tuberculosis targets and implementation of the political declaration of the United Nations high-level meeting of the General Assembly on the fight against tuberculosis](#). Report of the Secretary General. United Nations General Assembly, A/78/88.
5. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022 Feb 12;399(10325):629-655. Epub 2022 Jan 19. PMID: 35065702 PMCID: PMC8841637 DOI: 10.1016/S0140-6736(21)02724-0
6. <https://www.un.org/pga/77/2023/09/01/letter-from-the-president-of-the-general-assembly-health-related-processes-political-drafts/>
7. Horton R. Offline: Political declarations—clichés and lies. *Lancet* 2023; [Volume 402, Issue 10407](#), 23–29 September 2023, Page 1028. [https://doi.org/10.1016/S0140-6736\(23\)02023-8](https://doi.org/10.1016/S0140-6736(23)02023-8)
8. <https://www.stoptb.org/news/historic-political-declaration-tb-adopted-member-states-united-nations-high-level-meeting>
9. <https://www.globalfundadvocatesnetwork.org/wp-content/uploads/2023/09/Hub-Statement-on-the-Political-Declaration.pdf>
10. Ghebreyesus TA & Lima NT. The TB Vaccine Accelerator Council: harnessing the power of vaccines to end the tuberculosis epidemic. Published online 23 September 2023. [https://doi.org/10.1016/S1473-3099\(23\)00589-3](https://doi.org/10.1016/S1473-3099(23)00589-3)
11. [Stop TB launches its coalition of leaders against TB initiative](#).
12. Obiefuna AA. UN high level meeting must chart a path to TB elimination. *BMJ* 2023; 382:p1812 doi:10.1136/bmj.p1812
13. Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert H, Sari AH, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. *Lancet*, 2023, ISSN 0140-6736, [https://doi.org/10.1016/S0140-6736\(23\)01379-X](https://doi.org/10.1016/S0140-6736(23)01379-X)

ORCID

Kerry Millington <https://orcid.org/0009-0007-1988-1847>

Marc Lipman <https://orcid.org/0000-0001-7501-4448>

Finn McQuaid <https://orcid.org/0000-0001-6199-0931>

Richard White <https://orcid.org/0000-0003-4410-6635>

Jess Potter <https://orcid.org/0000-0002-6763-4425>

Ibrahim Abubakar <https://orcid.org/0000-0002-0370-1430>

Tom Wingfield <https://orcid.org/0000-0001-8433-6887>

Twitter

@KerryMillington

@richardwhite321

@CFMcQuaid

@JanikaHauser

@resultsuk

@DrJessPotter

@DrTomWingfield

Contributors

Conceived the manuscript: TW. Drafted the original manuscript: KAM. Contributed to the manuscript - review & editing: all authors.

Funding

KAM and TW work with the Leaving no one behind; transforming gendered pathways to health for TB (LIGHT) Research Programme Consortium funded by UK aid. RGW is funded by the Wellcome Trust (218261/Z/19/Z), NIH (1R01AI147321-01, G-202303-69963), EDTCP (RIA208D-2505B), UK MRC (CCF17-7779 via SET Bloomsbury), ESRC (ES/P008011/1), BMGF (INV-004737, INV-035506), and the WHO (2020/985800-0). TW is supported by grants from the Wellcome Trust, UK (209075/Z/17/Z), the Medical Research Council, Department for International Development, and Wellcome Trust (Joint Global Health Trials, MR/V004832/1), Medical Research Council (Public Health Intervention Development award, MR/Y503216/1), and the Medical Research Foundation (Dorothy Temple Cross International Collaboration Research Grant, MRF-131-0006-RG-KHOS-C0942).

This research has been partially funded by UK aid from the UK government (to KAM, TW), however, the views expressed do not necessarily reflect the UK government's official policies.

Competing interests

The authors declare no competing interests

Patient consent for publication

Not required.

Ethics approval

Not applicable.

Data availability statement

There are no data in this work.

Acknowledgments

None

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license for any Author Accepted Manuscript version arising.